Sarcoidosis remains difficult to diagnose, assess and treat. The last decade has brought significant diagnostic and therapeutic advances in the field of sarcoidosis including endobronchial ultrasound, 18F-fluorodeoxyglucose positron emission tomography and biologics. In this article we use clinical vignettes to discuss commonly encountered cases to illustrate and explain the application of these, and other advances.
HutchinsonJ.. Anomalous diseases of skin and fingers: case of livid papillary psoriasis? In: Illustrations of clinical surgery London: J and A Churchill; 1877. pp.42–3.
2.
SpagnoloP. Sarcoidosis: A Critical Review of History and Milestones. Clin Rev Allergy Immunol2015; 49: 1–5.
3.
CulverDA, JudsonMA. New advances in the management of pulmonary sarcoidosis. BMJ2019; 367: I5553.
WellsAU, HiraniN. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax2008; 63 (suppl 5): v1-58.
6.
HunninghakeGW, CostabelU, AndoM. ATS/ERS/ WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffus lung Dis1999; 16:149–73.
7.
ScaddingJ. Prognosis of Intrathoracic Sarcoidosis in England. BMJ1961; 2: 1165–72.
8.
GovenderP, BermanJ. Diagnosis of Sarcoidosis. Clin Chest Med2015; 36: 585–602.
9.
VisserH, VosK, ZanelliE. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis2002; 61: 499–504.
10.
BargagliE, BennettD, MaggiorelliC. Human chitotriosidase: a sensitive biomarker of sarcoidosis. J Clin Immuno2013; 33: 264–70.
11.
HarlanderM, MaverA, TerceljM. Common chitotriosidase duplication gene polymorphism and clinical outcome status in sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis2015; 32: 194–9.
12.
GruttersJ, FellrathJ, MulderL. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest2003; 124: 186–95.
BellNH, SternPH, PantzerE. Evidence that Increased Circulating 1a,25-Dihydroxyvitamin D is the Probable Cause for Abnormal Calcium Metabolism in Sarcoidosis. J Clin Invest1979; 64: 218–25.
15.
StuddyPR, BirdR. Serum angiotensin converting enzyme in sarcoidosis - Its value in present clinical practice. Ann Clin Biochem1989; 26: 13–8.
TeirsteinAS, JudsonMA, BaughmanRP. The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis, Vasc Diffus Lung Dis2005; 22: 139–46.
23.
AhmadzaiH, HuangS, SteinfortC. Sarcoidosis: a state of the art review from the Thoracic Society of Australia and New Zealand. Med J Aust2018; 208: 499–504.
24.
GuptaD, DadhwalDS, AgarwalR. Endobronchial ultrasound-guided transbronchial needle aspiration vs conventional transbronchial needle aspiration in the diagnosis of sarcoidosis. Chest2014; 146: 547–56.
25.
AgarwalR, SrinivasanA, AggarwalAN. Efficacy and safety of convex probe EBUS-TBNA in sarcoidosis: a systematic review and meta-analysis. Respir Med2012; 106: 883–92.
MaruchellaA, TondiniM. Reliability of bronchoalveolar lavage in the routine clinical assessment of patients with sarcoidosis. A retrospective analysis. Panminerva Med2002; 44: 257–60.
28.
TrisoliniR, TinelliC, CancellieriA. Transbronchial needle aspiration in sarcoidosis: Yield and predictors of a positive aspirate. J Thorac Cardiovasc Surg2008; 135: 837–42.
29.
ShorrAF, TorringtonKG, HnatiukOW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest2001; 120: 109–14.
30.
TakadaK, InaY, NodaM. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol1993; 46: 359–66.
31.
WellsAU. Sarcoidosis: A benign disease or a culture of neglect?Respir Med2018; 144S: S1–2.
ZappalaCJ, DesaiSR, CopleySJ. Optimal scoring of serial change on chest radiography in sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis2011; 28: 130–8.
34.
KirkilG, LowerEE, BaughmanRP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest2018; 153: 105–13.
35.
WalshSLF, WellsAU, SverzellatiN. An integrated clinicoradiological staging system for pulmonary sarcoidosis: A case-cohort study. Lancet Respir Med2014; 2: 123–30.
36.
KhanNA, DonatelliCV, TonelliAR. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med2017; 132: 9–14.
37.
CrommelinH, VorselaarsA, van MoorselC. Anti-TNF therapeutics for the treatment of sarcoidosis. Immunotherapy2014; 6: 1127–43.
38.
TetzlaffMT, NelsonKC, DiabA. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: A marker of therapy response in a subset of melanoma patients. J Immunother Cancer2018; 6: 1–11.
39.
BaughmanRP, LowerEE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax1999; 54: 742–6.
40.
CremersJ, DrentM, BastA. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med2013; 19: 545–61.
41.
BaltzanM, MehtaS, KirkhamTH. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med1999; 160: 192–7.
BennB, LehmanZ, KiddS. Sleep disturbance and symptom burden in sarcoidosis. Respir Med2018; 144S: S35–40.
49.
MostardR, van KroonenburghM, DrentM. The role of the PET scan in the management of sarcoidosis. Curr Opin Pulm Med2013; 19: 538–44.
50.
KeijsersRG, GruttersJC, ThomeerM. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging2011; 55: 66–71.
51.
Sobic-SaranovicD, ArtikoV, ObradovicV. FDG PET imaging in sarcoidosis. Semin Nucl Med2013; 43: 404–11.
52.
Case courtesy of Associate Prof Craig Hacking, Radiopaedia. org, rID:71482.
